Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fazadinium bromide is a non-depolarizing neuromuscular blocking agent used as a muscle relaxant in anesthesia. It acts as an antagonist at the nicotinic acetylcholine receptor at the neuromuscular junction, producing muscle relaxation by inhibiting synaptic transmission. The drug has a rapid onset and intermediate duration of action. It was marketed under the trade name Fazadon and is classified as a quaternary ammonium compound type muscle relaxant[1][6][7]. Its primary indication was to facilitate endotracheal intubation and provide skeletal muscle relaxation during surgery or mechanical ventilation[6]. The current marketing status is unknown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fazadinium bromide.